Cointime

Tricida

company

About

Tricida operates in the healthcare industry focusing on pharmaceutical business.

  • 51 - 100

Highlights

Total Funding Amount
$377.50M
Funding Rounds
6
Investors
2

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$125M
Industries
Health Care,Medical,Pharmaceutical
Founded date
Jan 1, 2013
Number Of Employee
51 - 100
Operating Status
Active

Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
6
$377.50M
Tricida has raised a total of $377.50M in funding over 2 rounds. Their latest funding was raised on Oct 19, 2022 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 19, 2022 Post-IPO Debt $125M 1 Hercules Capital — Detail
Mar 2, 2018 Debt Financing $100M 1 Hercules Capital — Detail
Nov 8, 2017 Series D $57.50M 1 — — Detail
Jul 25, 2016 Series C $55M 1 — — Detail
Mar 4, 2015 Series B $30M 1 — — Detail
Show More

Investors

Number of Lead Investors
Number of Investors
2
2
Tricida is funded by 2 investors. Hercules Capital and Limulus Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Yes Post-IPO Debt
Limulus Venture Partners — Series D
Cointime
เนื้อหา
บริษัท